Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies.

被引：0
|
作者：
Ottmann, O
Giles, F
Wassmann, B
Hochhaus, A
Rae, P
Beran, M
Albitar, M
Alland, L
Dugan, M
Kantarjian, H
机构：
[1] Univ Frankfurt, D-6000 Frankfurt, Germany
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Quest Diagnost, San Juan Capistrano, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195S / 195S
页数：1
相关论文
共 50 条
  • [1] Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies
    Ottmann, OG
    Giles, FJ
    Wassmann, B
    Wunderle, L
    Bhalla, K
    Jones, D
    Hochhaus, A
    Rae, PE
    Mietlowski, W
    Beran, M
    Albitar, M
    Alland, L
    Dugan, M
    Kantarjian, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 22 - 22
  • [2] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML)
    Giles, FG
    Ottmann, OT
    Cortes, J
    Wassmann, B
    Bhalla, K
    Jones, D
    Hochhaus, A
    Rae, PE
    Tanaka, C
    Alland, L
    Dugan, M
    Albitar, M
    Kantarjian, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 3 - 3
  • [3] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML).
    Kantarjian, H
    Ottmann, O
    Cortes, J
    Wassmann, B
    Jones, D
    Hochhaus, A
    Alland, L
    Dugan, M
    Albitar, M
    Giles, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 195S - 195S
  • [4] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    Golemovic, M
    Verstovsek, S
    Giles, F
    Cortes, J
    Manshouri, T
    Manley, PW
    Mestan, J
    Dugan, M
    Alland, L
    Griffin, JD
    Arlinghaus, RB
    Sun, T
    Kantarjian, H
    Beran, M
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4941 - 4947
  • [5] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
    E Weisberg
    P Manley
    J Mestan
    S Cowan-Jacob
    A Ray
    J D Griffin
    British Journal of Cancer, 2006, 94 : 1765 - 1769
  • [6] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
    Weisberg, E.
    Manley, P.
    Mestan, J.
    Cowan-Jacob, S.
    Ray, A.
    Griffin, J. D.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1765 - 1769
  • [7] Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
    E Weisberg
    P Manley
    J Mestan
    S Cowan-Jacob
    A Ray
    J D Griffin
    British Journal of Cancer, 2019, 121 : 282 - 282
  • [8] Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
    Weisberg, E
    Manley, PW
    Breitenstein, W
    Brüggen, J
    Cowan-Jacob, SW
    Ray, A
    Huntly, B
    Fabbro, D
    Fendrich, G
    Hall-Meyers, E
    Kung, AL
    Mestan, J
    Daley, GQ
    Callahan, L
    Catley, L
    Cavazza, C
    Mohammed, A
    Neuberg, D
    Wright, RD
    Gilliland, DG
    Griffin, JD
    CANCER CELL, 2005, 7 (02) : 129 - 141
  • [9] AMN107, a designed Bcr-Abl inhibitor effective in Gleevec-resistant CML
    不详
    CANCER BIOLOGY & THERAPY, 2005, 4 (03) : I - I
  • [10] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL)
    Kantarjian, HM
    Ottmann, O
    Hochhaus, A
    Mueller, M
    Cortes, J
    Wassmann, B
    Wunderle, L
    Bhalla, K
    Jones, D
    Rafferty, T
    Albitar, M
    Rae, L
    Dugan, M
    Alland, L
    Giles, F
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
12345